In a recent development for liver disease treatment, a new clinical trial has found that a popular weight-loss drug called Wegovy, which helps people lose weight by reducing their appetite and slowing the gut down, has given magical results for curing any sort of liver disease.
Patients suffering from a Fatty liver can be cured with this magical weight-loss drug. Wegovy contains a component known as semaglutide that is known to improve liver health significantly among patients.
Semaglutide is the same active ingredient present in other drugs such as Ozempic and Rybelsus. Although this study has offered hope for millions of people affected by Metabolic Dysfunction-associated steatohepatitis, commonly known as MASH, Nonalcoholic fatty liver disease affects about 33% of adults in the U.S., and about 5% to 7% of people have the advanced version of this disease, which is called MASH.
The results of this study were published on Wednesday in the New England Journal of Medicine, with results offering solutions for other conditions, such as addiction, dementia, and blood clotting.
Breakthrough in liver disease treatment
The last stage of the trial, funded by drugmaker Novo Nordisk, involved more than 800 participants with minimal to advanced levels of fibrosis due to MASH from over 37 countries. The results were amazing; it concluded that Wegovy reduced inflammation and scarring in people with MASH. Each patient got a weekly 2.4 milligram dose of semglutide for 72 weeks. Among 63% of those patients, there was a huge reduction in liver inflammation, compared with 34.3% of people who got a placebo.
Notably, over ⅓ of semaglutide recipients showed both inflammation reduction and fibrosis reversal, more than twice the rate seen in the other experimental group.
Dr. Susan Spratt, an endocrinologist and the senior medical director of the Population Health Management Office at Duke Health in North Carolina, said that “It is incredibly good news that semaglutide not only reduced inflammation but also that fibrosis regressed.”
Dr. Christopher McGowan, a gastroenterologist from Northern California, quoted in an email that “these findings represent a very promising step forward in the fight against a common and often silent disease.”
How does semaglutide help?
Semaglutide is known to mimic a natural gut hormone, GLP-1, that regulates a person’s appetite and insulin. It promotes weight loss, reduces fatty liver, and significantly decreases inflammation.
Why is this drug a game changer in chronic disease management?
Beyond its weight loss and diabetes control, semaglutide is increasingly being studied for its potential role in treating a range of chronic illnesses, from heart disease to kidney failure. As the global burden of metabolic diseases continues to grow, this miraculous component’s expanding role signals a transformative shift in preventive and therapeutic medicine.
Patients suffering from a Fatty liver can be cured with this magical weight-loss drug. Wegovy contains a component known as semaglutide that is known to improve liver health significantly among patients.
Semaglutide is the same active ingredient present in other drugs such as Ozempic and Rybelsus. Although this study has offered hope for millions of people affected by Metabolic Dysfunction-associated steatohepatitis, commonly known as MASH, Nonalcoholic fatty liver disease affects about 33% of adults in the U.S., and about 5% to 7% of people have the advanced version of this disease, which is called MASH.
The results of this study were published on Wednesday in the New England Journal of Medicine, with results offering solutions for other conditions, such as addiction, dementia, and blood clotting.
Breakthrough in liver disease treatment
The last stage of the trial, funded by drugmaker Novo Nordisk, involved more than 800 participants with minimal to advanced levels of fibrosis due to MASH from over 37 countries. The results were amazing; it concluded that Wegovy reduced inflammation and scarring in people with MASH. Each patient got a weekly 2.4 milligram dose of semglutide for 72 weeks. Among 63% of those patients, there was a huge reduction in liver inflammation, compared with 34.3% of people who got a placebo.
Notably, over ⅓ of semaglutide recipients showed both inflammation reduction and fibrosis reversal, more than twice the rate seen in the other experimental group.
Dr. Susan Spratt, an endocrinologist and the senior medical director of the Population Health Management Office at Duke Health in North Carolina, said that “It is incredibly good news that semaglutide not only reduced inflammation but also that fibrosis regressed.”
Dr. Christopher McGowan, a gastroenterologist from Northern California, quoted in an email that “these findings represent a very promising step forward in the fight against a common and often silent disease.”
How does semaglutide help?
Semaglutide is known to mimic a natural gut hormone, GLP-1, that regulates a person’s appetite and insulin. It promotes weight loss, reduces fatty liver, and significantly decreases inflammation.
Why is this drug a game changer in chronic disease management?
Beyond its weight loss and diabetes control, semaglutide is increasingly being studied for its potential role in treating a range of chronic illnesses, from heart disease to kidney failure. As the global burden of metabolic diseases continues to grow, this miraculous component’s expanding role signals a transformative shift in preventive and therapeutic medicine.
You may also like
Don't vote for me, but do not play with your life: Mamata Banerjee on Kolkata hotel fire
MP: Congress to launch caste census campaign in June
It's time for unacceptable Tottenham players to step up - but Ange Postecoglou sack truth remains
ITV's Dr Amir Khan lists five natural ways to lower your blood pressure
Manchester Marathon: Temperatures soar as record number complete 26.2 mile course
